CDT Equity Inc. Common Stock
CDTConduit Pharmaceuticals Inc. (CDT) is a biopharmaceutical company focused on developing innovative therapies for the treatment of inflammatory and autoimmune diseases. The company emphasizes research and development to create targeted medications aimed at improving patient outcomes in conditions such as rheumatoid arthritis and other chronic inflammatory disorders.
Company News
CDT Equity (NASDAQ:CDT) shares rose 14.71% to $4.68 on Monday despite the health care sector declining 2.63% over the past 30 days. The rally comes after the biopharmaceutical company disclosed a widened net loss of $39.1 million for 2025 and filed a non-timely 10K. Technical analysis shows the stock trading 49.1% below its 20-day moving average ...
CDT Equity Inc. (NASDAQ:CDT) announced multiple strategic initiatives to enhance shareholder value, including its 20% equity stake acquisition in Sarborg AI for $115 million, continued development of its pharmaceutical portfolio with AstraZeneca-licensed assets, and evaluation of capital markets initiatives to strengthen financial flexibility.
Conduit Pharmaceuticals has restructured a $2.65 million loan note with Nirland Limited, removing restrictive clauses and making the note convertible. The company has also secured $1.2 million in new promissory notes, positioning it to access its At-The-Market (ATM) facility to support its note repayment obligations, operations, and clinical obje...
Bloom Energy shares jumped 12.1% after announcing a strategic partnership with CoreWeave to deploy its fuel cells for on-site power generation at a data center. Several other stocks also saw significant pre-market movements, both positive and negative.
Conduit Pharmaceuticals shares traded higher by over 50% after the company announced it received patent approval for its lead asset targeting autoimmune diseases, which allows it to participate in the Patent Prosecution Highway and enhances the likelihood of approvals in major jurisdictions.